Core Viewpoint - Chunli Medical is set to unlock 209 million shares next week, with a market value of approximately 3.348 billion yuan, representing 263.74% of the pre-unlock circulating market value [1] Group 1: Share Unlocking Details - The type of shares being unlocked is additional commitment restricted shares, with the unlock date set for June 30, 2025 [1] - Major shareholders involved in this unlocking include Shi Chunbao (114 million shares) and Yue Shujun (95.4479 million shares) [1] Group 2: Company Overview - Beijing Chunli Zhengda Medical Device Co., Ltd. was established in 1998 and focuses on the continuous development and research of high-end medical devices, covering a full range of orthopedic products [2] - The company holds 124 medical device registration certificates and has expanded its product line to meet diverse market and clinical needs, enhancing its overall competitiveness [2] - Chunli Medical has a strong international presence, with products exported to over 50 countries and regions [2] Group 3: Research and Development - The company boasts a multidisciplinary team of experts with over 20 years of industry experience, providing strong intellectual support for technological innovation and business development [2] - Chunli Medical has received multiple qualifications, including being recognized as a national high-tech enterprise and a champion enterprise in the manufacturing sector [2] - The company actively participates in national and local research projects, contributing to advancements in the orthopedic field [2] Group 4: Market Position - As a leading enterprise in China's orthopedic industry, Chunli Medical has filled gaps in the domestic market with innovative products, establishing a unique market advantage [2] - The company aims to solve key technical challenges in the industry and enhance the level of independent innovation in the joint field [2] - Chunli Medical is committed to providing high-quality products globally, aspiring to become a world-renowned orthopedic enterprise [2]

Core Viewpoint - The announcement from Spring Medical indicates that a significant number of restricted shares, totaling 209 million shares or 54.52% of the total share capital, will be unlocked for trading on June 30, 2025, which may impact the company's stock liquidity and market dynamics [1][2]. Share Structure Changes - Before the unlocking, the number of restricted shares was 209.13 million, and after the unlocking, the number of unrestricted shares will increase to 383.56 million [2]. - The number of circulating shares before the unlocking was 17.44 million, which will rise to 38.4 million post-unlocking [1][2]. Stock Performance - As of June 19, the closing price of the company's stock was 16.85 CNY per share, with an initial offering price of 29.81 CNY per share, reflecting a decline of 43.48% from the offering price [2]. - The current stock price is 15.97 CNY per share, with a trailing twelve-month (TTM) price-to-earnings (P/E) ratio of 47.91, significantly higher than the industry average of 29.92 [3]. Financial Performance - For the most recent reporting period, the company reported revenue of 230 million CNY, a year-on-year increase of 3.6%, and a net profit attributable to shareholders of 58.07 million CNY, up 5.2% year-on-year [2]. - The net profit after excluding non-recurring items was 52.70 million CNY, reflecting a year-on-year increase of 7.81% [2]. - The net cash flow from operating activities was -75.34 million CNY, a year-on-year decline of 41.87% [2]. Company Overview - Spring Medical is primarily engaged in the research, development, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [3]. - The company's products are exported to various regions, including Asia, South America, Africa, Oceania, and Europe [3].

Core Viewpoint - The report from Huatai United Securities provides a thorough review of the listing and circulation of restricted shares for Beijing Chunli Zhengda Medical Devices Co., Ltd., confirming compliance with relevant regulations and the fulfillment of commitments by shareholders [1][8]. Group 1: Restricted Shares Overview - The restricted shares being listed for circulation are part of the company's initial public offering, involving two shareholders: Mr. Shi Chunbao and Ms. Yue Shujun. The original lock-up period of 36 months has been extended by 6 months due to the fulfillment of commitment conditions, now set to end on June 30, 2025 [2][6]. - The total number of restricted shares being released is 209,133,335, which accounts for 54.52% of the company's total share capital [6][8]. Group 2: Changes in Share Capital - The company's total share capital has changed from 384,280,000 shares to 383,568,500 shares since the formation of the restricted shares [2][4]. Group 3: Shareholder Commitments - Shareholders have made several commitments regarding their restricted shares, including not proposing buybacks and extending the lock-up period if the stock price falls below the IPO price for a specified duration [4][5]. - As of the date of the announcement, the shareholders have adhered to their commitments, ensuring no issues affecting the listing of restricted shares [5][8]. Group 4: Regulatory Compliance - Huatai United Securities has confirmed that the listing and circulation of the restricted shares comply with various regulatory frameworks, including the Securities Issuance and Listing Sponsorship Business Management Measures and the Shanghai Stock Exchange's rules [1][8].

证券代码：688236 证券简称：春立医疗 公告编号：2025-024 北京市春立正达医疗器械股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 本次股票上市流通总数为209,133,335股。 ? 本次股票上市流通日期为2025 年 6 月 30 日。 一、本次上市流通的限售股类型 本次上市流通的限售股为公司首次公开发行部分限售股，涉及限售股股东数 量为 2 名，为史春宝先生和岳术俊女士，原锁定期为自公司股票上市之日起 36 个 月，因触发延长股份锁定期的承诺履行条件，股份锁定期延长 6 个月至 2025 年 6 月 30 日。本次解除限售的股份数量为 209,133,335 股，占公司股本总数的 54.52%， 将于 2025 年 6 月 30 日起上市流通。 二、本次上市流通的限售股形成后至今公司股本数量变化情况 总股本由 384,280,000 股变更为 383,568,500 股。 除上述情形外，本次上市流通的限售股形成 ...

证券代码：688236 证券简称：春立医疗 公告编号：2025-024 北京市春立正达医疗器械股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 209,133,335股。 本次股票上市流通总数为209,133,335股。 本次股票上市流通日期为2025 年 6 月 30 日。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2021 年 11 月 22 日出具的《关于同意北京市 春立正达医疗器械股份有限公司首次公开发行股票注册的批复》（证监许可 [2021]3702 号），同意公司首次公开发行股票的注册申请。2021 年 12 月 30 日， 公司发行的 A 股股票在上海证券交易所科创板上市，本次发行股票数量为 38,428,000 股。发行完成后总股本为 384,280,000 股，其中有限售条件流通股的 A 股股票数量 256,582,500 股，无限售条件流通股的 A 股股票数量 ...

核查意见 华泰联合证券有限责任公司关于 北京市春立正达医疗器械股份有限公司 首次公开发行部分限售股上市流通的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"）作为北京市春立 正达医疗器械股份有限公司（以下简称"春立医疗"或"公司"）首次公开发行 股票并在科创板上市持续督导阶段的保荐机构，根据《证券发行上市保荐业务管 理办法》、《科创板上市公司持续监管办法（试行）》、《上海证券交易所科创 板股票上市规则》、《上海证券交易所科创板上市公司自律监管指引第 1 号—— 规范运作（2025 年 5 月修订）》等有关规定，对春立医疗首次公开发行部分限 售股上市流通的事项进行了审慎尽职调查，核查情况及核查意见如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2021 年 11 月 22 日出具的《关于同意北京 市春立正达医疗器械股份有限公司首次公开发行股票注册的批复》（证监许可 [2021]3702 号），同意公司首次公开发行股票的注册申请。2021 年 12 月 30 日， 公司发行的 A 股股票在上海证券交易所科创板上市，本次发行股票数量为 38,428,000 股。发行完成后总股本为 3 ...

Company Overview - Spring Medical is a Chinese company primarily engaged in the research, production, and sales of implantable orthopedic medical devices, established on February 12, 1998, and listed on December 30, 2021 [1] - The company's main products include joint prosthetics and spinal implant products, covering major human joints such as hip, knee, shoulder, and elbow, as well as a full range of spinal fixation systems [1] - The revenue composition of the company is 99.92% from medical device products and 0.08% from other sources [1] Stock Performance - On June 19, Spring Medical's stock price fell by 3.15%, closing at 15.97 yuan per share, with a trading volume of 27.87 million yuan and a turnover rate of 2.17%, resulting in a total market capitalization of 6.126 billion yuan [1] - The stock has experienced a continuous decline over three days, with a cumulative drop of 6.06% during this period [1] Fund Holdings - According to data from major funds, Nord Fund has a significant holding in Spring Medical, with the Nord New Prosperity Fund (005293) holding 70,000 shares, accounting for 4.66% of the fund's net value, making it the sixth-largest holding [2] - The fund has incurred a floating loss of approximately 36,400 yuan today and a total floating loss of 72,100 yuan during the three-day decline [2] Fund Manager Information - The fund manager of Nord New Prosperity Fund is Zhu Mingrui, who has been in the position for 2 years and 352 days, managing a total asset size of 63.1 million yuan [3] - During his tenure, the best fund return was 12.93%, while the worst return was -21.39% [3]

Company Overview - Spring Medical's closing price on June 18 was 16.49 yuan, down 2.54%, with a rolling PE ratio of 49.47 times and a total market capitalization of 6.325 billion yuan [1] - The company ranks 88th in the medical device industry, which has an average PE ratio of 49.10 times and a median of 36.43 times [1] - As of March 31, 2025, the number of shareholders increased to 7,167, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Spring Medical specializes in the research, production, and sales of implantable orthopedic medical devices [1] - The main products include spinal, trauma, joint, sports medicine implants, bone repair materials, surgical instruments, PRP preparation kits, and negative pressure wound drainage kits [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1] Financial Performance - In the first quarter of 2025, Spring Medical reported revenue of 230 million yuan, a year-on-year increase of 3.60% [1] - The net profit for the same period was 58.071 million yuan, reflecting a year-on-year growth of 5.20% [1] - The sales gross margin stood at 66.69% [1]

证券代码：688236 证券简称：春立医疗 公告编号：2025-023 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 年 月 日 2024 7 5 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 6 月 17 6 | 日-2025 | 年 | 月 | 16 | 日 | | 预计回购金额 | 2,000万元~4,000万元 | | | | | | | 回购价格上限 | 28.56元/股 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 实际回购股数 | 1,376,851股 | | | | | | | 实际回购股数占总股本比例 | 0.359% | | | | | | | 实际回购金额 | 20,008, ...

Market Overview - The Shanghai Composite Index closed at 3403.52 points, above the five-day moving average, with a slight increase of 0.11% [1] - The total trading volume of A-shares reached 808.39 billion yuan [1] Stocks Performance - A total of 253 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Shuguang Digital (14.08% deviation) - Sun Cable (8.01% deviation) - Suqian Liansheng (7.42% deviation) [1] Top Gainers - The top gainers today include: - Shuguang Digital: 22.27% increase, latest price at 61.87 yuan - Sun Cable: 10.00% increase, latest price at 6.82 yuan - Suqian Liansheng: 10.00% increase, latest price at 9.90 yuan [1] Additional Notable Stocks - Other stocks with notable performance: - Celery Medical: 9.97% increase, latest price at 13.46 yuan - Zhongke Shuguang: 10.00% increase, latest price at 68.09 yuan - Yuanwang Valley: 9.97% increase, latest price at 7.28 yuan [1]